Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

JNJ 10280205

Known as: JNJ-10280205, JNJ10280205 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties
Orally active, selective inhibitors of phosphodiesterase type 5 (PDE 5, cyclic GMP PDE), such as sildenafil, tadalafil and… Expand
  • figure 1
2006
2006
JNJ-10280205 and JNJ-10287069: novel PDE5 inhibitors as clinical candidates for erectile dysfunction
Phosphodiesterase 5 (PDE5) inhibitors are efficacious in treating patients with erectile dysfunction. New PDE5 inhibitors with… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE